Chemotherapy before and after surgery may be new standard treatment for some patients with oesophageal cancer

Immune therapy with belantamab mafodotin and elotuzumab shows encouraging safety profile and preliminary efficacy in RRMM

Transoral surgery and neck dissection with deintensified risk-based post-operative management increases efficacy in oropharynx cancer

Osimertinib success in locally advanced EGFR-mutated NSCLC

Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients

Adagrasib improves on docetaxel in previously treated NSCLC

Maintenance systemic therapy versus local consolidative therapy plus maintenance systemic therapy for NSCLC

Manageable safety profile with early efficacy of Tec-DR in NDMM

Inavolisib, palbociclib, fulvestrant combo shows sustained benefit beyond disease progression in HER2‑negative metastatic breast cancer

Neoadjuvant sacituzumab govitecan shows promising activity in muscle-invasive urothelial bladder cancer

Rates of pathologic complete response after neoadjuvant datopotamab deruxtecan in neoadjuvant breast cancer

Lutetium-177–PSMA-617 improves self-reported pain and HRQoL in taxane-naïve patients with PSMA-positive mCRPC